93 related articles for article (PubMed ID: 3924397)
1. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1985 Jul; 45(7):3173-8. PubMed ID: 3924397
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
3. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
4. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor.
Balch CM; Itoh K; Tilden AB
Surgery; 1985 Aug; 98(2):151-7. PubMed ID: 3875156
[TBL] [Abstract][Full Text] [Related]
5. In vitro generation of human activated lymphocyte killer cells: separate precursors and modes of generation of NK-like cells and "anomalous" killer cells.
Burns GF; Triglia T; Werkmeister JA
J Immunol; 1984 Sep; 133(3):1656-63. PubMed ID: 6611374
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes.
Han X; Itoh K; Balch CM; Pellis NR
Lymphokine Res; 1988; 7(3):227-35. PubMed ID: 3263554
[TBL] [Abstract][Full Text] [Related]
7. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
Itoh K; Tilden AB; Kumagai K; Balch CM
J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
[TBL] [Abstract][Full Text] [Related]
8. Interleukin 15 induction of lymphokine-activated killer cell function against autologous tumor cells in melanoma patient lymphocytes by a CD18-dependent, perforin-related mechanism.
Gamero AM; Ussery D; Reintgen DS; Puleo CA; Djeu JY
Cancer Res; 1995 Nov; 55(21):4988-94. PubMed ID: 7585540
[TBL] [Abstract][Full Text] [Related]
9. Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.
Gambacorti-Passerini C; Rivoltini L; Radrizzani M; Belli F; Sciorelli G; Ravagnani F; Galazka AR; Cascinelli N; Parmiani G
Cancer Res; 1989 Sep; 49(18):5230-4. PubMed ID: 2788498
[TBL] [Abstract][Full Text] [Related]
10. Generation of activated killer-like cells by OK-432-mediated production of interleukin 1, interleukin 2, and interferon-gamma in vitro.
Ujiie T
Jpn J Exp Med; 1987 Dec; 57(6):333-8. PubMed ID: 3131563
[TBL] [Abstract][Full Text] [Related]
11. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
Muralikrishna K; Varalakshmi C; Khar A
Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
[TBL] [Abstract][Full Text] [Related]
12. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
13. Activated lymphocyte killer cells derived from melanoma tissue or peripheral blood.
Burns GF; Good MF; Riglar C; Bartlett PF; Crapper RM; Mackay IR
Clin Exp Immunol; 1984 Aug; 57(2):487-94. PubMed ID: 6331928
[TBL] [Abstract][Full Text] [Related]
14. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
15. Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity.
Abdel-Wahab ZA; Osanto S; Darrow TL; Barber JR; Vervaert CE; Gangavalli R; McCallister TJ; Seigler HF
Cancer Gene Ther; 1994 Sep; 1(3):171-9. PubMed ID: 7621248
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
17. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells.
Möller P; Möller H; Sun Y; Dorbic T; Henz BM; Wittig B; Schadendorf D
Cancer Gene Ther; 2000 Jul; 7(7):976-84. PubMed ID: 10917199
[TBL] [Abstract][Full Text] [Related]
18. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxicity tests against cultured human lung cancer cells with autologous lymphocytes activated in vitro by mitomycin C-treated tumor monolayers in the presence of T-cell growth factor.
Kimura H; Yamaguchi Y; Kadoyama C; Sato N; Fujisawa T
Jpn J Clin Oncol; 1983 Mar; 13(1):3-13. PubMed ID: 6300483
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
